Establishment of three human breast epithelial cell lines derived from carriers of the 999del5 BRCA2 Icelandic founder mutation
- PMID: 16448223
- DOI: 10.1007/s11626-005-0005-3
Establishment of three human breast epithelial cell lines derived from carriers of the 999del5 BRCA2 Icelandic founder mutation
Abstract
Germ line mutations in BRCA1 and BRCA2 account for a large proportion of inherited breast and ovarian cancer. Both genes are involved in DNA repair by homologous recombination and are thought to play a vital role in maintaining genomic stability. A major drawback for long-term functional studies of BRCA in general and BRCA2 in particular has been a lack of representative human breast epithelial cell lines. In the present study, we have established three cell lines from two patients harboring the 999del5 germ line founder mutation in the BRCA2 gene. Primary cultures were established from cellular outgrowth of explanted tissue and subsequently transfected with a retroviral construct containing the HPV-16 E6 and E7 oncogenes. Paired cancer-derived and normal-derived cell lines were established from one patient referred to as BRCA2-999del5-2T and BRCA2-999del5-2N, respectively. In addition, one cell line was derived from cancer-associated normal tissue from another patient referred to as BRCA2-999del5-1N. All three cell lines showed characteristics of breast epithelial cells as evidenced by expression of breast epithelial specific cytokeratins. Cytogenetic analysis showed marked chromosomal instability with tetraploidy and frequent telomeric associations. In conclusion, we have established three breast epithelial cell lines from two patients carrying the BRCA2 Icelandic 999del5 founder mutation. These cell lines form the basis for further studies on carcinogenesis and malignant progression of breast cancer on a defined genetic background.
Similar articles
-
The Icelandic founder mutation BRCA2 999del5: analysis of expression.Breast Cancer Res. 2004;6(4):R284-90. doi: 10.1186/bcr785. Epub 2004 Apr 7. Breast Cancer Res. 2004. PMID: 15217494 Free PMC article.
-
Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families.Eur J Hum Genet. 2001 Oct;9(10):773-9. doi: 10.1038/sj.ejhg.5200717. Eur J Hum Genet. 2001. PMID: 11781689
-
Prostate cancer progression and survival in BRCA2 mutation carriers.J Natl Cancer Inst. 2007 Jun 20;99(12):929-35. doi: 10.1093/jnci/djm005. Epub 2007 Jun 12. J Natl Cancer Inst. 2007. PMID: 17565157
-
Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2.Hum Mutat. 2002 Dec;20(6):413-24. doi: 10.1002/humu.10154. Hum Mutat. 2002. PMID: 12442265 Review.
-
Chromosomal mutagen sensitivity associated with mutations in BRCA genes.Cytogenet Genome Res. 2004;104(1-4):325-32. doi: 10.1159/000077511. Cytogenet Genome Res. 2004. PMID: 15162060 Review.
Cited by
-
Establishment and characterization of three new human breast cancer cell lines derived from Chinese breast cancer tissues.Cancer Cell Int. 2009 Jan 2;9:2. doi: 10.1186/1475-2867-9-2. Cancer Cell Int. 2009. PMID: 19121212 Free PMC article.
-
A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability.Cell. 2017 Jun 1;169(6):1105-1118.e15. doi: 10.1016/j.cell.2017.05.010. Cell. 2017. PMID: 28575672 Free PMC article.
-
Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.Gene Ther. 2017 Oct;24(10):601-609. doi: 10.1038/gt.2017.73. Epub 2017 Aug 3. Gene Ther. 2017. PMID: 28771233 Review.
-
Northern lights assay: a versatile method for comprehensive detection of DNA damage.Nucleic Acids Res. 2018 Nov 16;46(20):e118. doi: 10.1093/nar/gky645. Nucleic Acids Res. 2018. PMID: 30053193 Free PMC article.
-
Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition.Invest New Drugs. 2012 Apr;30(2):425-34. doi: 10.1007/s10637-010-9566-4. Epub 2010 Oct 20. Invest New Drugs. 2012. PMID: 20960027
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous